Blueprint Medicines Corp
BPMC129.460USD
0.000
收盘 10/10, 16:00（美东）报价延迟15分钟
8.36B总市值
亏损市盈率 TTM
关于 Blueprint Medicines Corp 公司
Blueprint Medicines Corporation 是一家全球精准治疗公司，正在过敏/炎症和肿瘤/血液学两个领域发明改变生命的药物。该公司向美国和欧洲的患者提供其获批的药物，包括 AYVAKIT/AYVAKYT (avapritinib) 和 GAVRETO (pralsetinib)，并在全球范围内推进针对系统性肥大细胞增多症 (SM)、肺癌、乳腺癌和其他基因组定义的癌症以及癌症免疫疗法的多个项目。该公司的产品线还包括 Elenestinib (BLU-263) (KIT)、AYVAKIT (avapritinib) (KIT)、野生型 KIT 研究项目、GAVRETO (pralsetinib) (RET)、BLU-945 (EGFR)、BLU-525 (EGFR)、BLU-451 (EGFR 外显子 20 插入)、BLU-222 (CDK2)、AYVAKIT (PDGFRA)、GAVRETO (RET)、BLU-222 (CDK2) 和 BLU-852 (MAP4K1)。该公司正在开发一种口服、有效且高选择性的试验性 KIT 抑制剂 Elenestinib (BLU-263)，用于治疗惰性 SM 和其他肥大细胞疾病。
Blueprint Medicines Corp简介
公司代码BPMC
公司名称Blueprint Medicines Corp
上市日期Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
员工数量649
证券类型Ordinary Share
年结日Apr 30
公司地址45 Sidney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02139
电话16173747580
网址https://www.blueprintmedicines.com/
公司代码BPMC
上市日期Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Blueprint Medicines Corp公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024Q3
FY2024Q2
FY2024Q1
业务USD
名称
营收
占比
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
地区USD
名称
营收
占比
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
业务
地区
业务USD
名称
营收
占比
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
股东统计
更新时间: 8月13日 周三
更新时间: 8月13日 周三
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
其他
63.83%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
其他
63.83%
股东类型
持股股东
占比
Investment Advisor
42.13%
Hedge Fund
26.61%
Investment Advisor/Hedge Fund
24.80%
Research Firm
3.16%
Sovereign Wealth Fund
1.66%
Individual Investor
0.93%
Bank and Trust
0.78%
Pension Fund
0.78%
Venture Capital
0.41%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
701
68.81M
106.41%
-3.22M
2025Q1
702
71.75M
110.98%
-1.27M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
--
0%
-223.92K
-100.00%
T. Rowe Price Associates, Inc.
--
0%
-3.95M
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
-182.70K
-100.00%
State Street Global Advisors (US)
--
0%
-453.14K
-100.00%
Geode Capital Management, L.L.C.
--
0%
+18.37K
-100.00%
Macquarie Investment Management
--
0%
-364.73K
-100.00%
AllianceBernstein L.P.
--
0%
-430.85K
-100.00%
查看更多
持股ETF
更新时间: 8月6日 周三
更新时间: 8月6日 周三
机构名称
占比
ProShares Merger ETF
3.21%
AltShares Event-Driven ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.92%
Goldman Sachs Future Health Care Equity ETF
0.84%
Hypatia Women CEO ETF
0.73%
First Trust Mid Cap Growth AlphaDEX Fund
0.58%
iShares Russell 2000 Growth ETF
0.54%
WisdomTree BioRevolution Fund
0.49%
SoFi Next 500 ETF
0.45%
JPMorgan Fundamental Data Science Small Core ETF
0.43%
查看更多
ProShares Merger ETF
占比3.21%
AltShares Event-Driven ETF
占比1.43%
ProShares Ultra Nasdaq Biotechnology
占比0.92%
Goldman Sachs Future Health Care Equity ETF
占比0.84%
Hypatia Women CEO ETF
占比0.73%
First Trust Mid Cap Growth AlphaDEX Fund
占比0.58%
iShares Russell 2000 Growth ETF
占比0.54%
WisdomTree BioRevolution Fund
占比0.49%
SoFi Next 500 ETF
占比0.45%
JPMorgan Fundamental Data Science Small Core ETF
占比0.43%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
